Achillion Pharmaceuticals Inc. (ACHN) and Akebia Therapeutics Inc. (NASDAQ:AKBA) Comparison side by side

Both Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and Akebia Therapeutics Inc. (NASDAQ:AKBA) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achillion Pharmaceuticals Inc. N/A 0.00 68.64M -0.51 0.00
Akebia Therapeutics Inc. 234.48M 2.27 192.59M -2.40 0.00

Table 1 highlights Achillion Pharmaceuticals Inc. and Akebia Therapeutics Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Achillion Pharmaceuticals Inc. 0.00% -26.8% -25.9%
Akebia Therapeutics Inc. -82.13% -23.8% -12.1%

Volatility & Risk

A 2.42 beta indicates that Achillion Pharmaceuticals Inc. is 142.00% more volatile compared to Standard and Poor’s 500. Akebia Therapeutics Inc.’s 31.00% more volatile than Standard and Poor’s 500 which is a result of the 1.31 beta.

Liquidity

23.3 and 23.3 are the respective Current Ratio and a Quick Ratio of Achillion Pharmaceuticals Inc. Its rival Akebia Therapeutics Inc.’s Current and Quick Ratios are 1.8 and 1.3 respectively. Achillion Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Akebia Therapeutics Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Achillion Pharmaceuticals Inc. and Akebia Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Achillion Pharmaceuticals Inc. 0 0 1 3.00
Akebia Therapeutics Inc. 0 1 2 2.67

Achillion Pharmaceuticals Inc.’s upside potential currently stands at 83.95% and an $5.5 consensus target price. Meanwhile, Akebia Therapeutics Inc.’s consensus target price is $15.67, while its potential upside is 247.45%. Based on the analysts belief we can conclude, Akebia Therapeutics Inc. is looking more favorable than Achillion Pharmaceuticals Inc.

Institutional and Insider Ownership

Roughly 77.6% of Achillion Pharmaceuticals Inc. shares are held by institutional investors while 69.7% of Akebia Therapeutics Inc. are owned by institutional investors. Insiders held 0.15% of Achillion Pharmaceuticals Inc. shares. Insiders Competitively, held 1.1% of Akebia Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achillion Pharmaceuticals Inc. 9.71% -3.79% 29.24% 6.64% -15.04% 91.82%
Akebia Therapeutics Inc. -1.7% -17.52% -10.23% -35.38% -44.49% 4.7%

For the past year Achillion Pharmaceuticals Inc.’s stock price has bigger growth than Akebia Therapeutics Inc.

Summary

On 6 of the 11 factors Achillion Pharmaceuticals Inc. beats Akebia Therapeutics Inc.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.